Augurix and Tillotts Pharma sign agreement for the commercialization of Simtomax®

7 Sep 2011

Augurix and Tillotts Pharma AG, a specialty pharma company with a leading position in the field of gastroenterology with its headquarters in Rheinfelden, Switzerland, are pleased to announce that they have entered into a commercialization agreement for Simtomax®, Augurix’ rapid point-of-care diagnostic test for celiac disease.
The agreement grants Tillotts the exclusive right to distribute and supply Simtomax® in dedicated key European markets.

Download the press release (also in French).


Back to the news page »